AGREEing on Nutritional Management of Patients with CKD—A Quality Appraisal of the Available Guidelines

Dimitra Rafailia Bakaloudi 1, Lydia Chrysoula 1, Kalliopi Anna-Poulia 2, Evangelia Dounousi 3, Vassilios Liakopoulos 4 and Michail Chourdakis 1

1 Laboratory of Hygiene, Social & Preventive Medicine and Medical Statistics, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece; dimitrabakaloudi@gmail.com (D.R.B.); lydian285@gmail.com (L.C.); mhourd@gapps.auth.gr (M.C.)
2 Department of Nutrition and Dietetics, Laiko General Hospital, 11527 Athens, Greece; lpoulia@gmail.com
3 Department of Nephrology, Faculty of Medicine, School of Health Sciences, University of Ioannina, 45110 Ioannina, Greece; evangeldou@gmail.com
4 Division of Nephrology and Hypertension, 1st Department of Internal Medicine, AHEPA Hospital, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece
* Correspondence: liakopul@otenet.gr; Tel.: +30-2310-994694

Abstract: Chronic kidney disease (CKD) is an important public health issue with increasing prevalence worldwide. Several clinical practice guidelines have been recently published regarding the nutritional management of CKD patients. The purpose of the present study is to evaluate the quality of the published guidelines and provide recommendation for future updates. PubMed, Scopus and Google Scholar were searched for relevant guidelines and 11 clinical practice guidelines were finally included. Guidelines developed by the American Society for Parenteral and Enteral nutrition (ASPEN), the Dietitians Association of Australia (DAA), the German Society for Nutritional Medicine (DGEM), the European Best Practice Guidelines (EBPG), the European Dialysis and Transplantation Nurses Association-European Renal Care Association (EDTNA-ERCA), the European Society for Clinical Nutrition and Metabolism (ESPEN), the Andalusian Group for Nutrition Reflection and Investigation (GARIN) group, the National Kidney foundation-Kidney Disease Outcomes Quality Initiative (KDOQI), the Italian Society of Nephrology-Association of Dieticians-Italian Association of Hemodialysis, Dialysis and Transplant (SIN-ANDID-ANED), and the Renal Association were assessed using the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool. Guidelines by KDOQI, ESPEN, and DAA were of moderate quality and the rest of them were low-quality guidelines. Our study demonstrates gaps related to the development of guidelines and therefore greater emphasis on methodological approaches is recommended. AGREE II tool can be useful to improve quality of guidelines.

Keywords: AGREE; chronic kidney disease; clinical practice; guidelines; nutrition support; nutritional status; recommendations

1. Introduction

Chronic kidney disease (CKD) remains a strong cause of adverse health outcomes, with a constant rise in prevalence and a recorded 41.5% global increase from 1990 to 2017 in all age-mortality rates [1]. It was estimated that in 2017, 697.5 million people were diagnosed with any stage of CKD, which is equivalent to a 9.1% prevalence worldwide [1]. Furthermore, it is expected that the number of patients receiving renal replacement therapy (RRT) will be doubled by 2030, with the highest increase predicted for Asia and North America. This will eventually lead to a higher total cost of treatment, especially for patients with comorbidities, resulting in an economic burden on healthcare systems [2,3]. In order to avoid such a trend and avert an additional financial pressure on health systems, the
development of low-cost strategies towards the prevention and reduction in the adverse outcomes of CKD is essential, if not critical [4].

It has been well established that lifestyle and dietary modifications are a cost-effective strategy, producing both cost- and health-related benefits [5–7]. In addition, improved nutritional status and compliance with the medical nutrition guidance has been positively associated with a better quality of life (QoL) and cognitive function, lower risk of complications (e.g., hypertension, dyslipidemia, obesity, cardiovascular, the progression of CKD, etc.), reduced risk of malnutrition and overall CKD-related symptoms [8–10]. Therefore, it is essential for health professionals to comprehend the importance and complexity of the provision of nutritional support in these patients and emphasize the formulation and delivery of appropriate nutritional treatment followed by regular monitoring [11,12]. Such actions require the systematic development of clinical guidelines in order to ensure patients’ safety and provision of high-quality nutritional care [13].

Clinical practice guidelines can be defined as evidence-based statements and recommendations aiming to enhance health outcomes of patients and simultaneously assist health professionals in their decision-making processes and implementation of individualized patient care [14]. So far, a number of clinical guidelines have been published by several scientific societies, as well as international institutions and organizations, aiming to ensure the best nutritional management for patients with CKD. However, clinical practice guidelines often present high heterogeneity and a number of questions over their validity, reliability, applicability in clinical practice, transparency, and methodological rigor have been raised. In addition, there has not been any attempt to assess the quality and the development process of nutritional practice guidelines for patients with CKD. The aim of this study is to critically appraise the quality of existing clinical practice guidelines on the nutritional management of CKD and to identify their limitations and discrepancies with regard to structure, methodology, and development. Moreover, the provision of suggestions for potential areas of quality improvement is another scope of the present work, using the revised Appraisal of Guidelines for Research and Evaluation tool (AGREE II), an international tool that has been widely used in the past 10 years for the quality assessment of medical guidelines, as the appraisal instrument [15].

2. Materials and Methods

Systematic searches on PubMed, Scopus and Google scholar databases were performed (until 12th of November 2020) using the follow search string (guidelines OR recommendations OR statements) AND (CKD OR renal failure OR chronic kidney disease OR kidney failure) AND (nutrition OR diet OR nutritional management) for the PubMed database; this was modified accordingly for the other databases (see Supplementary File 1). From a total 5687 results and after removing duplicates and irrelevant studies, 297 studies were screened for eligibility. Inclusion criteria were recently published nutritional guidelines for patients with CKD, developed by scientific societies and/or associations. Irrelevant recommendations, hospital internal guidelines or recommendations referring only to subjects <18 years old were excluded. Finally, 11 clinical practice guidelines published from 2003 until 2020 were retrieved [16–26]. Clinical practice guidelines by the American Society for Parenteral and Enteral nutrition (ASPEN) [16], the Dietitians Association of Australia (DAA) [17], the German Society for Nutritional Medicine (DGEM) [18], the European Best Practice Guidelines (EBPG) [19], the European Dialysis and Transplantation Nurses Association-European Renal Care Association (EDTNA-ERCA) [20], the European Society for Clinical Nutrition and Metabolism (ESPEN) [21,22], the Andalusian Group for Nutrition Reflection and Investigation (GARIN) group [23], the National Kidney foundation-Kidney Disease Outcomes Quality Initiative (KDOQI) [24], the Italian Society of Nephrology-Association of Dieticians-Italian Association of Hemodialysis, Dialysis and Transplant (SIN-ANDID-ANED) [25], and the Renal Association [26] were reviewed and evaluated using the AGREE II tool. [15] Translations of original clinical practice guidelines were excluded. The latest updated version of each guideline was selected for guidelines
with previous published versions. Characteristics of eligible clinical practice guidelines that were included can be found in Table 1.

**Guideline Appraisal**

Four authors, including medical doctors, nutritionists, and dietitians (DB, LC, KAP and MC), independently evaluated and appraised the 11 practice guidelines with the use of the AGREE II tool [15]. Each reviewer ratings can be found in Supplementary File 2. The AGREE tool was first developed in 2003 in an effort to provide researchers with an instrument that would aid in the quality assessment, reporting, evaluation, and improvement of clinical practice guidelines within various health settings [27]. The AGREE II tool, which is the updated version, consists of a reporting checklist including 23 items categorized under the following six main quality domains: 1. scope and purpose, 2. stakeholder involvement, 3. rigor of development, 4. clarity of presentation, 5. Applicability, and 6. editorial independence, as well as two more items under “overall assessment” concerning the overall quality of the guideline and recommendations on whether or not it should be used in practice [15]. Each item is rated using a 7-point scale (1 = strongly disagree, 7 = strongly agree). Finally, the total score for each domain is calculated by summing up all ratings for all items of each domain and then expressed as a percentage of the maximum possible score in each domain, minus the minimum possible score as follows:

\[
\frac{\text{Obtained score} - \text{Minimun possible score}}{\text{Maximum possible score} - \text{Minimum possible score}} \times 100
\]

In order to ensure the consistency regarding the evaluation of the included guidelines, specific quality thresholds were set. High-quality and “recommended” guidelines were those with scores ≥70% for all domains; moderate quality and “recommended with modifications” guidelines were those with scores ≥70% in three to five domains; low-quality and not recommended guidelines were those with scores ≥70% in none of the domains or up to two domains.
Table 1. Characteristics of included guidelines.

| No. | Developer | Year | Region | Intended Population | Scope/Grading System | Number of References | Disciplines Involved in the Group |
|-----|-----------|------|--------|---------------------|----------------------|---------------------|-----------------------------------|
| 1   | ASPEN     | 2010 | USA    | Adult patients with AKI and CKD | Provision of nutrition support to patients with AKI and CKD/Level of evidence I–V | 64                  | Physicians, nurses, pharmacologists, dieticians |
| 2   | DAA *     | 2006 | Australia | Adults with CKD | Dietetic management of adult patients with CKD/Level of evidence I–IV | 19                  | Dietitians, nephrologists, renal nurses |
| 3   | DGEM *    | 2015 | Germany | Adults with AKD, CKD, dialysis and transplant patients | Nutrition support and metabolic management in the care of patients with renal dysfunction/No info | 77                  | Physicians |
| 4   | EBPG      | 2007 | Europe | Adult patients on dialysis | Prevalence, diagnosis and treatment of malnutrition of patients on dialysis/No info | 337                 | Dietitians, nephrologists |
| 5   | EDTNA-ERCA | 2003 | Europe | Adults with CKD | Support healthcare professionals on the task of nutrition advice of renal patients/No info | 53                  | Physicians, dietitians, nurses |
| 6   | ESPEN     | 2006 | Europe | Adult patients with renal failure and patients on dialysis | Recommendations for the use of ONS and TF in nephrology patients/Grade A–C | 72                  | No info |
| 7   | ESPEN     | 2009 | Europe | Adult patients with renal failure and patients on dialysis | Indications for parenteral nutrition in renal patients with malnutrition/Grade A–C | 123                 | Physicians, dietitians |
| 8   | GARIN     | 2018 | Spain  | Adult patients with CKD stages 1–5 (including patients on dialysis) | Define dietary characteristics for adults with renal diseases/GRADE-ASPEN | 96                  | Endocrinology and nutrition specialists |
Table 1. Cont.

| No. | Developer # | Year | Region | Intended Population                                                                 | Scope/Grading System                                                                                                                                                                                                 | Number of References | Disciplines Involved in the Group                                                                 |
|-----|-------------|------|--------|--------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------|---------------------------------------------------------------------------------------------------|
| 9   | KDOQI *     | 2020 | International | Adult patients with CKD stages 1–5, (including patients on dialysis), and patients with functional kidney transplant | Provision of MNT guidelines for patients with CKD to assess, prevent, and treat protein-energy wasting, mineral and electrolyte disorders, and other metabolic comorbid conditions associated with CKD/Grade A-D                                                                 | 531                  | Physicians, registered dietitians-nutritionists, researchers, methodologists with expertise in the renal and nutrition field |
| 10  | Renal Association | 2019 | UK     | Adult patients with CKD stages 4 and 5 (including dialysis)                            | Prevalence, diagnosis and treatment of undernutrition in chronic kidney disease/The modified GRADE system                                                                                                                | 75                   | No information                                                                                     |
| 11  | SIN-ANDID-ANED | 2018 | Italy   | Adult patients with advanced renal insufficiency                                     | Promotion of a successful and safe implementation of nutritional treatment for CKD patients/No info                                                                                                                        | 167                  | Nephrologists, dietitians, patients                                                               |

CKD: Chronic kidney disease, NA: Not Applicable, AKI: Acute Kidney Injury, AKD: Acute Kidney Disease, GRADE: Grading of Recommendations Assessment, Development and Evaluation, MNT: Medical Nutrition Therapy, ONS: Oral Nutritional Supplements, TF: Tube feeding, UK: United Kingdom. ASPEN: American Society for Parenteral and Enteral Nutrition, DAA: Dietitians Association of Australia, DGEM: Deutsche Gesellschaft für Ernährungsmedizin-German Society for Nutritional Medicine, EBPG: European Best Practice Guidelines, EDTNA-ERCA: European Dialysis and Transplantation Nurses Association/European Renal Care Association, ESPEN: European Society for Clinical Nutrition and Metabolism, KDOQI: Kidney Disease Outcomes Quality Initiative, SIN-ANDID-ANED: Italian Society of Nephrology-Association of Dieticians-Italian Association of Hemodialysis, Dialysis and Transplant, and GARIN: Andalusian Group for Nutrition Reflection and Investigation. # All developers are medical/nutritional societies. * Updated version of guidelines.
3. Results

Results of the evaluations of the 11 clinical practice guidelines can be found in Table 2. Three clinical practice guidelines were found to be of moderate quality [17,21,24]. High-quality clinical guidelines for the nutritional management of patients with CKD were not found according to the parameters of the AGREE II tool. The lowest score, i.e., one point per reviewer, is equal to 14.3% in terms of percentage in the AGREE tool II and reflects either the poor description of the relevant information or its total absence from the guideline.

3.1. Scope and Purpose Domain

The majority of the clinical practice guidelines received high ratings in the domain of “scope and purpose”, while six of them received a score ≥70% [17,18,21–24]. Four guidelines received low scores [16,20,25,26] and the EBPG guideline received the lowest [19].

3.2. Stakeholder Involvement Domain

In this domain, none of the included guidelines were highly rated by the four reviewers. Five studies had rates of 40–70%, which translates into a moderate quality [16–18,24,25], whereas in the remaining six studies had rate scores <40%, leading to low-quality characterization [19–23,26]. Item 2b, “target population’s views and preferences”, was sufficiently stated in only two guidelines (DAA and SIN-ANDIN-ANED) [17,25]. Moreover, item 2a, which refers to the expertise and the roles of members taking part in the guideline development group, was only reported in the KDOQI guidelines [24].

3.3. Rigor of Development

The results for the domain “rigor of development” varied. This domain evaluates all stages of the methodological development of each guideline review as well as information on the update process. The highest score can be observed in the KDOQI guidelines [24], whereas in the other guidelines many items of this domain were not included [16,17,19–22,25,26] or were not satisfactorily described [18,23].

3.4. Clarity of Presentation

Regarding the clarity of presentation, the results were satisfactory. Clinical practice guidelines developed by DGEM received the highest scores (100) [18]. High scores were also reported in seven clinical practice guidelines which scored >70% [17,19–24] and three guidelines were determined to be of moderate quality [16,25,26]. None of the guidelines received a low score for this domain.

3.5. Applicability

As per the domain of “Applicability”, none of the included clinical practice guidelines received a total score ≥70%. Moreover ASPEN, SIN-ANDID-ANED and the Renal Association received scores of zero as they failed to mention this aspect in their manuscripts [16,25,26].

3.6. Editorial Independence

In this domain, the reviewers appraised the included clinical practice guidelines according to the information provided for the funding and the authors’ conflicts of interest during the guideline development. In eight guidelines, exclusive funding statements were found [16–18,20,21,23–25], but information on whether this funding influenced the content of guidelines was not always reported (i.e., DGEM, EDTNA-ERCA, and SIN-ANDID-ANED guidelines [18,20,25]). In the ASPEN and DAA guidelines, no funding existed [16,17]. Moreover, statements of competing interest were not found in the ASPEN and GARIN guidelines [16,23].

The average quality score of each domain between recommended with modifications and not recommended guidelines can be seen in Figure 1 and a summary of the AGREE II tool results of each domain can be found in Supplementary Figure S1.
Table 2. Appraisal of Guidelines for Research and Evaluation (AGREE) II results for clinical practice guidelines.

| Domains                          | Clinical Practice Guidelines | ASPEN [16] | DAA [17] | DGEM [18] | EBPG [19] | EDTNA-ERCA [20] | ESPEN (EN) [21] | ESPEN (PN) [22] | GARIN [23] | KDOQI [24] | SIN-ANDID-ANED [25] | The Renal Association [26] |
|----------------------------------|-------------------------------|------------|---------|----------|--------|-----------------|-----------------|----------------|-------------|-----------|----------------------|-----------------------------|
| **1. SCOPE AND PURPOSE**         |                               | 34.7       | 88.9    | 88.9     | 0.00   | 62.5            | 77.8            | 81.9           | 86.1        | 88.9     | 55.6                 | 5.6                        |
| a. Overall objectives            |                               | 75.0       | 85.7    | 82.1     | 14.3   | 75.0            | 71.4            | 89.3           | 89.3        | 89.3     | 60.7                 | 25.0                       |
| b. Health questions              |                               | 17.9       | 96.4    | 89.3     | 14.3   | 53.6            | 85.7            | 89.3           | 89.3        | 89.3     | 100                  | 14.3                       |
| c. Population to apply           |                               | 39.3       | 89.3    | 100      | 14.3   | 75.0            | 85.7            | 75.0           | 89.3        | 92.0     | 57.1                 | 17.9                       |
| **2. STAKEHOLDER INVOLVEMENT**   |                               | 62.5       | 63.9    | 44.4     | 16.7   | 34.7            | 36.1            | 12.5           | 15.3        | 51.4     | 43.1                 | 18.1                       |
| a. Guideline development group   |                               | 85.7       | 75.0    | 64.3     | 53.6   | 32.1            | 53.6            | 42.9           | 39.3        | 100      | 71.4                 | 32.1                       |
| b. Views and preferences of target population |                   | 28.6       | 71.4    | 14.3     | 17.9   | 32.1            | 14.3            | 14.3           | 14.5        | 53.6     | 14.3                 | 14.3                       |
| c. Users of guidelines           |                               | 89.3       | 60.7    | 78.6     | 14.3   | 67.9            | 67.9            | 17.9           | 28.6        | 57.1     | 28.6                 | 42.9                       |
| **3. RIGOR OF DEVELOPMENT**      |                               | 31.3       | 30.2    | 48.9     | 21.9   | 13.0            | 36.5            | 18.2           | 74.7        | 72.4     | 3.6                  | 33.3                       |
| a. Research methodology          |                               | 32.1       | 32.1    | 82.1     | 14.3   | 14.3            | 17.9            | 14.3           | 50.0        | 96.4     | 14.3                 | 60.7                       |
| b. Selecting criteria            |                               | 14.3       | 17.9    | 14.2     | 14.3   | 14.3            | 17.9            | 75.0           | 100         | 14.3     | 14.3                 | 14.3                       |
| c. Strengths and limitations of evidence |                         | 14.3       | 14.3    | 28.6     | 14.3   | 14.3            | 17.9            | 85.7           | 85.7        | 14.3     | 42.9                 |                           |
| d. Formulating methods           |                               | 46.4       | 42.9    | 50.0     | 14.3   | 17.9            | 39.3            | 25.0           | 32.1        | 82.1     | 14.3                 | 53.6                       |
| e. Health benefits, side effects and risks stated in recommendations |                         | 75.0       | 14.3    | 92.9     | 82.1   | 67.9            | 75.0            | 57.1           | 32.1        | 25.0     | 25.0                 |                            |
| f. Explicit link of recommendations |                              | 89.3       | 82.1    | 92.9     | 82.1   | 46.4            | 96.4            | 60.7           | 96.4        | 100      | 28.6                 | 71.4                       |
| g. Review of guideline           |                               | 42.9       | 57.1    | 14.3     | 14.3   | 14.3            | 28.6            | 14.3           | 28.6        | 100      | 14.3                 | 60.7                       |
| h. Updating procedure            |                               | 14.3       | 60.7    | 89.3     | 14.3   | 14.3            | 78.6            | 14.3           | 14.3        | 14.3     | 14.3                 | 14.3                       |
| **4. CLARITY OF PRESENTATION**   |                               | 52.8       | 84.7    | 100      | 86.1   | 91.7            | 94.4            | 91.7           | 94.4        | 98.6     | 33.3                 | 68.1                       |
| a. Specific and unambiguous recommendations |                       | 67.9       | 83.3    | 100      | 89.3   | 96.4            | 89.3            | 100            | 96.4        | 100      | 46.4                 | 85.7                       |
| b. Different options for management |                             | 14.3       | 92.9    | 100      | 75.0   | 85.7            | 96.4            | 96.4           | 96.4        | 96.4     | 25.0                 | 60.7                       |
| c. Identifiable key recommendations |                               | 96.4       | 96.4    | 100      | 96.4   | 96.4            | 82.1            | 100            | 100         | 100      | 57.1                 | 71.4                       |
| **5. APPLICABILITY**             |                               | 0.0        | 11.5    | 12.5     | 27.1   | 36.5            | 4.2             | 33.3           | 25.0        | 62.5     | 0.0                  | 0.0                        |
| a. facilitators and barriers of application |                       | 14.3       | 14.3    | 14.3     | 17.9   | 32.1            | 14.3            | 14.3           | 14.3        | 28.6     | 14.3                 | 14.3                       |
| b. guideline implementation advice and tools |                    | 14.3       | 21.4    | 14.3     | 60.7   | 67.9            | 14.3            | 67.9           | 57.1        | 96.4     | 14.3                 | 14.3                       |
| c. Resource implications         |                               | 14.3       | 21.4    | 14.3     | 28.5   | 28.6            | 14.3            | 14.3           | 17.9        | 57.1     | 14.3                 | 14.3                       |
| d. Monitoring and/or auditing criteria |                       | 14.3       | 39.3    | 57.1     | 42.9   | 53.6            | 28.6            | 75.0           | 53.6        | 89.3     | 14.3                 | 14.3                       |
| **6. EDITORIAL INDEPENDENCE**    |                               | 35.4       | 100     | 47.9     | 0.00   | 36.5            | 95.8            | 6.3            | 39.6        | 91.7     | 50.8                 | 47.9                       |
| a. Views of funding body         |                               | 75.0       | 100     | 21.4     | 14.3   | 17.9            | 96.4            | 14.3           | 82.1        | 85.7     | 42.9                 | 14.3                       |
| b. Conflicts of interests        |                               | 14.3       | 100     | 89.3     | 14.3   | 17.9            | 96.4            | 25.0           | 14.3        | 100      | 71.4                 | 96.4                       |
| **OVERALL QUALITY**              |                               |            |         |          |        |                 |                 |                |             |          |                     |                            |
| Low                             | Moderate                      | Low        | Low     | Low      | Low    | Low             | Moderate        | Low            | Moderate     | Low      | Low                  |                            |

All results are presented as percentage scores. Total score of each domain and the highest score of each category are presented in bold font. EN: Enteral nutrition; PN: Parenteral nutrition. AoND: Academy of Nutrition and Dietetics, ASPEN: American Society for Parenteral and Enteral Nutrition, DAA: Dietitians Association of Australia, DGEM: Deutsche Gesellschaft für Ernährungsmedizin-German Society for Nutritional Medicine, EBPG: European Best Practice Guidelines, EDTNA-ERCA: European Dialysis and Transplantation Nurses Association/European Renal Care Association, ESPEN: European Society for Clinical Nutrition and Metabolism, KDOQI: Kidney Disease Outcomes Quality Initiative, GARIN: Andalusian Group for Nutrition Reflection and Investigation.
Figure 1. Average quality score of each domain between recommended with modifications and not recommended guidelines.
4. Discussion

The aim of the present study was to assess the quality of development of 11 nutritional guidelines for patients with CKD using the AGREE II tool [15]. According to our results, scores between the domains of each guideline differed significantly. Clinical guidelines developed by the KDOQI received the highest rating (≥70% in four domains) [24], followed by ESPEN (EN) and DAA guidelines (≥70% in three domains) [17,21] and were recommended with modifications by the reviewers. Moreover, clinical guidelines by ASPEN, DGEM, EBPG, EDTNA–ERCA, ESPEN (PN), GARIN, SIN–ANDID–ANED, and the Renal Association [16,18–20,22,23,25,26] were characterized by a low overall quality and thus were not recommended based on the AGREE II tool [15].

Based on the AGREE II reported items, there are several fields in the quality of guidelines that could be improved. In general, sufficient evidence for the purpose and scope (Domain 1) can be found in the guidelines studied. Regarding this domain, EPBG [19] and the Renal Association [26] failed to clearly describe the population covered by the guidelines. Clarifying purpose and scope can prohibit the use of guidelines for a non-appropriate group of patients.

As for the stakeholder involvement (Domain 2), more information about expertise, geographical location as well as the role of each member in guideline development could improve the significance of EDTNA-ERCA, GARIN, and the Renal Association guidelines [20,23,26], as an emphasis on multidisciplinary approaches could have a positive impact on the quality of the guidelines. Population experiences and expectations were not adequately described in the included guidelines and this should be considered for the future updated versions. Moreover, target users’ information is missing in the EBPG [19] guideline, which should be clearly defined so as the clinician can recognize whether the guideline is appropriate for his/her use.

As per rigor of development (Domain 3), the intense heterogeneity that was found between the scores (Table 2) proves the existence of significant gaps regarding the guidelines’ methodological development. Only in the KDOQI [24] guideline description and methods of evidence selection were described. This is the domain in which several modifications are needed (i.e., better description of research methodology, report of included/excluded criteria, strengths and potential limitations of guideline development, link between scientific evidence and recommendations, etc.) in order to improve the quality of the existing clinical practice guidelines.

In most of the guidelines examined, recommendations were clearly presented (Domain 4), facilitating the easy accessibility and application by the clinician, something that is important especially in acute settings. Tables, summarizing boxes, bold font, and/or numbers were used in all analyzed nutritional guidelines and/or key recommendations. Moreover, only in the SIN-ANDID-ANED guideline [25], the item of different options for management in patients with CKD was not satisfactorily described, a parameter that indicates that a different approach according to stage and the severity of CKD is needed, as claimed by the majority of included guidelines. An important parameter that should be highlighted is that although the AGREE II tool includes the item regarding different options for management, consideration of the patient’s condition in the very beginning of their treatment is missing. None of the 11 guidelines examined included satisfactory statements for the first approach according to the condition of the patient. For example, novel, ketogenic diets, prescribed by trained physicians, could prove helpful for obese patients with mild CKD [28,29], but in recently published guidelines, special recommendations for this group of patients were not stated.

As per applicability, an important domain of the AGREE II instrument (Domain 5), all nutritional guidelines failed to adequately report facilitators and barriers and/or provide tools, advice, and potential resources that can affect implementation in clinical practice; consequently, in all guidelines, the total obtained score for this domain was <70%. The best described item of this domain was that of monitoring, which was only not applicable for ASPEN, SIN-ANDID-ANED, and the Renal Association clinical practice guidelines [16,25,26].
Finally, the evidence of funding and/or conflicts of interest were not informative in all cases. Only in the DAA [17] clinical practice guideline was editorial independence (Domain 6) entirely described. The fact that funding body information and/or competing interest statements are not clearly and adequately described can be associated with several biases regarding the content of recommendations. As the AGREE II tool can sufficiently identify the problematic areas in the clinical practice guidelines, it is highly recommended that this tool should be used by guidelines developers as a checklist with a view to keeping structure and adequacy in guideline development methodology and to ensuring the high quality of the guidelines produced.

Our study has several strengths. First, to the best of our knowledge, this is the first study that compares and evaluates the quality of the clinical practice guidelines in nutritional management of patients with CKD. Moreover, the assessment and rating of the eligible guidelines was performed independently by a multidisciplinary group of four reviewers, including medical doctors and dieticians. Furthermore, it is the first time that the AGREE II tool has been used for the quality evaluation of the nutritional practice guidelines for CKD.

One of the limitations of our study is that we included guidelines in English, Spanish, and German and we may have excluded other published guidelines in different languages. Moreover, the fact that nine out of 11 guidelines included in our study came from European regions could mean that the results of our study might be difficult to be applied to patients in other regions. In addition, the appraisal tool does not provide standard cut offs for the evaluation of scores and this could affect the interpretation of our results. Furthermore, it should be clarified that in this study, only the critical appraisal of the quality development of the guidelines was performed without any assessment of the quality of the guidelines’ content.

5. Conclusions

The quality of the development of the majority of the nutritional clinical practice guidelines on management of CKD patients it is not satisfactory. The guidelines that were the best in terms of quality according to the AGREE II tool were the KDOQI, DAA, and ESPEN (EN), ensuring a better quality of information, even if they all require modifications in future update processes [17,21,24]. Additionally, as several gaps in methodology development were identified in most of the guidelines, the following updates should incorporate these changes in order to ameliorate their quality. Editorial independence should be described in detail in order to eliminate bias. AGREE II can be a useful tool in the evaluation of quality of clinical practice guidelines.

Supplementary Materials: The following are available online at https://www.mdpi.com/2072-6643/13/2/624/s1, Supplementary File 1: Search strategy, Supplementary File 2: Ratings of each reviewer, Supplementary Figure S1: AGREE II tool results of each domain.

Author Contributions: D.R.B., L.C. and K.A.-P. wrote the paper; K.A.-P., V.L., E.D. and M.C. made the necessary recommendations, K.A.-P., V.L. and M.C. revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations

ASPDEN American Society for Parenteral and Enteral Nutrition
CKD Chronic kidney disease
DAA Dietitians Association of Australia
EBPG European best practice guidelines
EDTNA-ERCA European Dialysis and Transplantation Nurses Association-European Renal Care Association
ESPEN European Society for Clinical Nutrition and Metabolism
KDOQI Kidney disease outcomes quality initiative
MNT Medical nutrition therapy
QoL Quality of life
RRT Renal replacement therapy
SIN-ANDID-ANED Italian Society of Nephrology-Association of Dieticians-Italian Association of Hemodialysis, Dialysis and Transplant

References

1. GBD Chronic Kidney Disease Collaboration; Purcell, C.A.; Levey, A.S.; Smith, M.; Abdoli, A.; Abebe, M.; Adebayo, O.M.; Afarideh, M.; Agarwal, S.K.; Agudelo-Botero, M.; et al. Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2020, 395, 709–733. [CrossRef]
2. Liyanage, T.; Ninomiya, T.; Jha, V.; Neal, B.; Patrice, H.M.; Okpechi, I.; Zhao, M.-H.; Lv, J.; Garg, A.X.; Knight, J.; et al. Worldwide access to treatment for end-stage kidney disease: A systematic review. *Lancet* 2015, 385, 1975–1982. [CrossRef]
3. Manns, B.; Hemmelgarn, B.; Tonelli, M.; Au, F.; So, H.; Weaver, R.; Quinn, A.E.; Klarenbach, S.; Canadians Seeking Solutions and Innovations to Overcome Chronic Kidney Disease. The Cost of Care for People With Chronic Kidney Disease. *Can. J. Kidney Health Dis.* 2019, 6, 2054358119835521. [CrossRef] [PubMed]
4. Vanholder, R.; Annemans, L.; Brown, E.; Gansevoort, R.; Gout-Zwart, J.J.; Lameire, N.; Morton, R.L.; Oberbauer, R.; Postma, M.J.; Tonelli, M.; et al. Reducing the costs of chronic kidney disease while delivering quality health care: A call to action. *Nat. Rev. Nephrol.* 2017, 13, 393–409. [CrossRef]
5. Elia, M.; Normand, C.; Norman, K.; Laviano, A. A systematic review of the cost and cost effectiveness of using standard oral nutritional supplements in the hospital setting. *Clin. Nutr.* 2016, 35, 370–380. [CrossRef]
6. Freijer, K.; Bours, M.J.; Nuijten, M.; Foley, M.J.; Meijers, J.M.; Halfens, R.J.; Schols, J.M. The economic value of enteral medical nutrition in the management of disease-related malnutrition: A systematic review. *J. Am. Med Dir. Assoc.* 2014, 15, 17–29. [CrossRef]
7. Sharma, Y.; Thompson, C.; Miller, M.; Shahi, R.; Hakendorf, P.; Horwood, C.; Kaambwa, B. Economic evaluation of an extended nutritional intervention in older Australian hospitalized patients: A randomized controlled trial. *BMC Geriatr.* 2018, 18, 41. [CrossRef]
8. Campbell, K.L.; Ash, S.; Bauer, J.D. The impact of nutrition intervention on quality of life in pre-dialysis chronic kidney disease patients. *Clin. Nutr.* 2008, 27, 537–544. [CrossRef]
9. Lopes, I.M.; Martin, M.; Errasti, P.; Martinez, J.A. Benefits of a dietary intervention on weight loss, body composition, and lipid profile after renal transplantation. *Nutrition* 1999, 15, 7–10. [CrossRef]
10. Palmer, S.C.; Maggo, J.K.; Campbell, K.L.; Craig, J.C.; Johnson, D.W.; Sutanto, B.; Ruospo, M.; Tong, A.; Strippoli, G.F.M. Dietary interventions for adults with chronic kidney disease. *Cochrane Database Syst. Rev.* 2017. [CrossRef]
11. Institute of Medicine Committee on Nutrition Services for Medicare Beneficiaries. *The Role of Nutrition in Maintaining Health in Nation's Elderly*; National Academies Press: Washington, DC, USA, 2000. [CrossRef] [PubMed]
12. Kovesdy, C.P.; Kopple, J.D.; Kalantar-Zadeh, K. Management of protein-energy wasting in non-dialysis-dependent chronic kidney disease: Reconciling low protein intake with nutritional therapy. *Am. J. Clin. Nutr.* 2013, 97, 1163–1177. [CrossRef]
13. Woolf, S.H.; Grol, R.; Hutchinson, A.; Eccles, M.; Grimshaw, J. Clinical guidelines: Potential benefits, limitations, and harms of clinical guidelines. *BMJ Clin. Res. Ed.* 1999, 318, 527–530. [CrossRef] [PubMed]
14. Graham, R.; Mancher, M.; Miller Wolman, D.; Greenfield, S.; Steinberg, E. (Eds.) Institute of Medicine Committee on Standards for Developing Trustworthy Clinical Practice, Guidelines. In *Clinical Practice Guidelines We Can Trust*; National Academies Press: Washington, DC, USA, 2011. [CrossRef]
15. Brouwers, M.C.; Kho, M.E.; Brown, G.P.; Burgers, J.S.; Cluzeau, F.; Feder, G.; Fervers, B.; Graham, I.D.; Grimshaw, J.; Hanna, S.E.; et al. AGREE II: Advancing guideline development, reporting and evaluation in health care. *J. Clin. Epidemiol* 2010, 63, 1308–1311. [CrossRef] [PubMed]
16. Brown, R.O.; Compher, C. A.S.P.E.N. clinical guidelines: Nutrition support in adult acute and chronic renal failure. *JPEN J. Parenter. Enter. Nutr.* 2010, 34, 366–377. [CrossRef] [PubMed]
17. Ash, S.; Campbell, K.; MacLaughlin, H.; McCoy, E.; Chan, M.; Anderson, K; Corke, K.; Dumont, R.; Lloyd, L.; Meade, A.; et al. Evidence based practice guidelines for the nutritional management of chronic kidney disease. *Nutr. Diet.* 2006, 63, S33–S45. [CrossRef]
18. Druml, W.; Contzen, B.; Joannidis, M.; Kierdorf, H.; Kuhlmann, M.K.; das DGEM Steering Committee. S1-Leitlinie der Deutschen Gesellschaft für Ernährungsmedizin (DGEM) in Zusammenarbeit mit der AKE, der GESKES und der DGN. Aktuelle Ernährungsmed. 2015, 40, 21–37. [CrossRef]

19. Fouque, D.; Vennegoor, M.; Ter Wee, P.; Warner, C.; Basci, A.; Canaud, B.; Haage, P.; Konner, K.; Kooman, J.; Martin-Malo, A.; et al. EBPG Guideline on Nutrition. Nephrol. Dial. Transplant. 2007, 22, i145–i187. [CrossRef]

20. James, G.; Jackson, H. European Guidelines for the Nutritional Care of Adult Renal Patients. EDTNA-ERCA J. 2003, 29, 23–43. [CrossRef]

21. Cano, N.; Fiaccadori, E.; Tesinsky, P.; Toigo, G.; Druml, W.; Kuhlmann, M.; Mann, H.; Hörl, W.H. ESPEN Guidelines on Enteral Nutrition: Adult renal failure. Clin. Nutr. 2006, 25, 295–310. [CrossRef]

22. Cano, N.J.; Aparicio, M.; Brunori, G.; Carrero, J.J.; Cianciaruso, B.; Fiaccadori, E.; Lindholm, B.; Teplan, V.; Fouque, D.; Guarnieri, G. ESPEN Guidelines on Parenteral Nutrition: Adult renal failure. Clin. Nutr. 2009, 28, 401–414. [CrossRef]

23. Alhambra-Expósito, M.-R.; Molina-Puerta, M.-J.; Oliveira, G.; Arраiza-Irigoyen, C.; Fernández-Soto, M.; García-Almeida, J.-M.; García-Luna, P.-P.; Gómez-Pérez, A.-M.; Irle-Rocamora, J.-A.; Molina-Soria, J.-B.; et al. Recomendaciones del grupo GARIN para el tratamiento dietético de los pacientes con enfermedad renal crónica. Nutr. Hosp. 2019, 36, 183–217. [CrossRef]

24. Ikizler, T.A.; Burrowes, J.D.; Byham-Gray, L.D.; Campbell, K.L.; Carrero, J.-J.; Chan, W.; Fouque, D.; Friedman, A.N.; Ghaddar, S.; Goldstein-Fuchs, D.J.; et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. Am. J. Kidney Dis. 2020, 76, S1–S107. [CrossRef]

25. Cupisti, A.; Brunori, G.; Di Iorio, B.R.; D’Alessandro, C.; Pasticci, F.; Cosola, C.; Bellizzi, V.; Bolasco, P.; Capitanini, A.; Fantuzzi, A.L.; et al. Nutritional treatment of advanced CKD: Twenty consensus statements. J. Nephrol. 2018, 31, 457–473. [CrossRef]

26. Wright, M.; Southcott, E.; MacLaughlin, H.; Wineberg, S. Clinical practice guideline on undernutrition in chronic kidney disease. BMC Nephrol. 2019, 20, 370. [CrossRef]

27. Development and validation of an international appraisal instrument for assessing the quality of clinical practice guidelines: The AGREE project. Qual. Saf. Health Care 2003, 12, 18–23. [CrossRef]

28. Masi, D.; Risi, R.; Basciani, S.; Tuccinardi, D.; Mariani, S.; Lubrano, C.; Gnnessi, L.; Watanabe, M. Very Low-Calorie Ketogenic Diets to Treat Patients With Obesity and Chronic Kidney Disease. J. Ren. Nutr. Off. J. Counc. Ren. Nutr. Natl. Kidney Found. 2020. [CrossRef]

29. Watanabe, M.; Tuccinardi, D.; Ernesti, I.; Basciani, S.; Mariani, S.; Genco, A.; Manfrini, S.; Lubrano, C.; Gnnessi, L. Scientific evidence underlying contraindications to the ketogenic diet: An update. Obes. Rev. 2020, 21, e13053. [CrossRef]